Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2010-01-19
2011-12-13
Olson, Eric S (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S305000
Reexamination Certificate
active
08076346
ABSTRACT:
The present invention relates to a composition and a method of delivering a barbituric acid derivative to the central nervous system of a mammal in need of treatment for neurological conditions. In particular, the present invention relates to a method of administering an oral dosage form of a sodium salt of 5,5-diphenyl barbituric acid to enhance the bioavailability of 5,5-diphenyl barbituric acid and brain delivery of same.
REFERENCES:
patent: 1960170 (1934-05-01), Schnider
patent: 2119701 (1938-06-01), Callsen
patent: 2673205 (1954-03-01), Hoffmann et al.
patent: 3679683 (1972-07-01), Gorbaty
patent: 3711607 (1973-01-01), Vida et al.
patent: 3900475 (1975-08-01), Vida et al.
patent: 5756815 (1998-05-01), Knell
patent: 5808066 (1998-09-01), Krummel et al.
patent: 5985856 (1999-11-01), Stella et al.
patent: 6051737 (2000-04-01), Kim et al.
patent: 6093820 (2000-07-01), Gutman et al.
patent: 6156925 (2000-12-01), Meyer et al.
patent: 6184238 (2001-02-01), Takano et al.
patent: 6262067 (2001-07-01), Allen et al.
patent: 6281207 (2001-08-01), Richter et al.
patent: 6372757 (2002-04-01), Johns et al.
patent: 6638528 (2003-10-01), Kanios
patent: 6664262 (2003-12-01), Gutman et al.
patent: 6756379 (2004-06-01), Moros et al.
patent: 6906079 (2005-06-01), Gutman et al.
patent: 6939873 (2005-09-01), Gutman et al.
patent: RE38934 (2006-01-01), Gutman et al.
patent: 7064205 (2006-06-01), Gutman et al.
patent: 7166610 (2007-01-01), Moros
patent: 7214658 (2007-05-01), Tobinick
patent: 7227021 (2007-06-01), Gutman et al.
patent: 7683071 (2010-03-01), Gutman et al.
patent: 7723346 (2010-05-01), Moros et al.
patent: 7776871 (2010-08-01), Moros
patent: 2003/0018080 (2003-01-01), Gutman et al.
patent: 2003/0153589 (2003-08-01), Moros et al.
patent: 2003/0187005 (2003-10-01), Gutman et al.
patent: 2004/0167358 (2004-08-01), Gutman et al.
patent: 2004/0186120 (2004-09-01), Moros
patent: 2004/0224947 (2004-11-01), Moros et al.
patent: 2006/0004031 (2006-01-01), Gutman et al.
patent: 2006/0009450 (2006-01-01), Tobinick
patent: 2006/0035915 (2006-02-01), Gutman et al.
patent: 2006/0122208 (2006-06-01), Gutman et al.
patent: 2006/0205747 (2006-09-01), Moros et al.
patent: 2006/0258864 (2006-11-01), Gutman et al.
patent: 2007/0072886 (2007-03-01), Moros
patent: 2007/0167624 (2007-07-01), Gutman et al.
patent: 2010/0197709 (2010-08-01), Moros et al.
patent: 2010/0311771 (2010-12-01), Moros
patent: 946804 (1956-08-01), None
patent: 1100639 (1961-03-01), None
patent: 1103339 (1961-03-01), None
patent: 1939787 (1970-02-01), None
patent: 2622981 (1977-12-01), None
patent: 4028040 (1992-03-01), None
patent: 726252 (1996-08-01), None
patent: 726252 (1996-08-01), None
patent: 1083172 (2001-03-01), None
patent: 966098 (1964-08-01), None
patent: WO-9918084 (1999-04-01), None
patent: WO-01/39779 (2001-06-01), None
patent: WO-01/79185 (2001-10-01), None
patent: WO-02/07729 (2002-01-01), None
patent: WO-03/063872 (2003-08-01), None
patent: WO-2004/052350 (2004-06-01), None
patent: WO-2006/003651 (2006-01-01), None
patent: WO-2006/026095 (2006-03-01), None
Aldrich Chemical Catalog, 1990-1991, p. 303.
Alles et al. “Comparative central depressant actions of some 5-phenyl-5-alky barbituric acids” (J. Pharmacol Exp. Ther.) 1947, 89: 356-367.
Appendix 1 of U.S. Appl. No. 60/352,273, filed Jan. 30, 2002: Chemical Derivative Chart (total of 8 pages).
Appendix 2 of U.S. Appl. No. 60/352,273, filed Jan. 30, 2002: References to Chemical Derivatives (total of 3 pages).
Appendix 3 of U.S. Appl. No. 60/352,273, filed Jan. 30, 2002: MEDLINEpIus of Jan. 15, 2002: Barbiturates (Systemic) (total of printout 14 pages).
Appendix 3 of U.S. Appl. No. 60/352,273, filed Jan. 30, 2002: PubMed search results printout of Jan. 15, 2002 (total of 7 pages).
Appendix 3 of U.S. Appl. No. 60/352,273, filed Jan. 30,2002: CANCERLIT . . . (total of 9 pages).
Balas, I et al. “Talamotomia esterotaxica de la enfermedad de Parkinson y otros tipos de temblor. Experiencias de la actividad multiunitaria burst en el talamo basada en semimicroelectrodos” Rev. Neurol., 2001, 32 (6): 520-524; I.. (English Abstract).
Barnes, Harry M. et al., “For Further Observations on the Condensation of Benzene with Alloxan” (J. Am. Chem. Soc.) Jul.-Dec. 1937, 59: 2348-2351.
Bashir, K. et al.: “Clozapine for the control of hemiballismus,” Clinical Neuropharmacology, vol. 17, No. 5, 1994, pp. 477-480, XP009032005.
Baumel et al. “Metabolism and anticonvulsant properties of primidone in the rat” (J. Pharmacol Exp. Ther.) 1973, 186: 305-314.
Beers et al., ed., Merck Manual of Diagnosis and Therapy, Seventeenth Edition, (1999), Chapter 179, pp. 1462-1473.
Berge et al. “Pharmaceutical Salts” Journal of Pharmaceutical Sciences (1977) vol. 66, No. 1, pp. 1-19.
Bertram et al., “Phenobarbital is superior to phenytoin as an antiepileptic, neuroprotectant and antiepileptogenic agent in a rat model of status epilepticus and chronic limbic epilepsy,” Epilepsia, vol. 37, No. Suppl. 5, p. 140 (1996); and Annual Meeting of the American Epilepsy Society, San Francisco, CA, USA, Dec. 7-10, 1996.
Bhardwaj et al., “Pentobarbital inhibits extracellular release of dopamine in the ischemic striatum”, Journal of Neural Transmission [Gen Sect], 82, pp. 111-117, (1990).
Breimer et al. “Pharmacokinetics and relative bioavailbility of heptabarbital and heptabarbital sodium after oral administration to man” (Eur. J. Clin. Pharmacology) 1975, 9: 169-178.
Brint et al., “Focal brain ischemia in the rat: Methods for reproducible neocortical infarction using tandem occlusion of the distal middle cerebral and ipsilateral common carotid arteries”, J. Cerebral Blood Flow Metab., 8, pp. 474-485, (1988).
Broderick et al., “Guidelines for the Management of Spontaneous Intracerebral Hemorrhage,” Stroke, vol. 30, pp. 905-915, 1999.
Casagrande, C. et al., “Synthesis and antiarrhythmic activity of 5,5-disubstituted-3-aminoalkylhydantoins and some heterocyclic and noncyclic analogs”, retrieved from STN Database accession No. 1975:43261, Farmaco, Edizione Scientific, 29(10) 757-785, 1974.
Casara et al., “Synthesis of acid stable fluorinated acyclonucleosides as potential antiviral agents,” Tetrahedron Letters, 32(31) (1991), pp. 3823-3826.
Clinician, “Essential Tremor: A Practical Guide to Evaluation, Diagnosis, and Treatment” May 2001, vol. 19, No. 2, pp. 1-15.
Constantino et al., “Metabotropic glutamate receptors: targets for therapy of cerebral ischaemia,” Expert Opinion on Therapeutic Drugs, vol. 5, pp. 669-683, 2001.
Corkill et al., Surg. Neural., pp. 147-149 (1976).
Craig et al. “Metabolism and anticonvulsant properties of mephobarbital and phenobarbital in rats” (J. Pharmacol Exp. Ther.) 1971, 176: 35-41.
Depakene Product Information, Abbott Laboratories, revised Apr. 2009.
Dietrichson, P., et al., “Primidone and Propranolol in Essential Tremor: A Study Based on Quantitative Tremor Recording and Plasma Anticonvulsant Levels”, Acta Neurol Scand., 1987:75:332-340.
Doak et al., Pharmacotherapy, vol. 18, No. 3, pp. 637-645, 1998.
Dox et al “5,5-Diarylbarbituric Acids” (J. Chem. Soc.) 1923, 45: 1811-1816.
European Search report issued in EP Application EP 01 95 9195, dated Feb. 24, 2006.
European Search report issued in EP Application EP 05 29 0804, dated Jun. 16, 2005.
European Search report issued in EP Application No. 03 01 1817, completed Jul. 14, 2003.
European Search report issued in EP Application No. 03 73 5068, dated Feb. 28, 2006.
European Search report issued in EP Application No. 05 78 6192 , dated Nov. 22, 2007.
Fahn, Stanley et al. “Clinical Rating Scale for Tremor”, Parkinson's Disease and Movement Disorders, Urban & Schwarzenberg, Inc., 1988, 17: 225-234.
Findley, Leslie J. et al., “Primidone in Essential Tremor of the Hands and Head: A Double Blind Controlled Clinical Study”, Journal of Neurology, Neurosurgery, and Psychi
Gutman Daniella
Levitt Barrie
Moros Daniel A.
Rutman Howard
Yacobi Avraham
Alathari Zayd
Haddaway Keith G.
Olson Eric S
Taro Pharamaceutical Industries Ltd.
Venable LLP
LandOfFree
Composition and method for improved bioavailability and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method for improved bioavailability and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for improved bioavailability and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4260148